@drgdiddy It’s $JNJ JNJ-379 ability to inhibit cccDNA formation intracellularly, that‘s important. Suppression of replenishment of cccDNA production in cell nucleus is a BIG DEAL. Along with JNJ-3989 (formally $ARWR ARO-HBV) RNAi-therapy + Nuc, they‘ll have a successful HBV-drug regimen.